US Stock MarketDetailed Quotes

TGTX TG Therapeutics

Watchlist
  • 30.710
  • -0.020-0.07%
Close Feb 14 16:00 ET
  • 30.710
  • 0.0000.00%
Post 20:01 ET
4.78BMarket Cap-307.10P/E (TTM)

About TG Therapeutics Company

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Company Profile

SymbolTGTX
Company NameTG Therapeutics
Listing DateOct 7, 2005
Founded1993
CEOMr. Michael S. Weiss
MarketNASDAQ
Employees264
Fiscal Year Ends12-31
Address3020 Carrington Mill Boulevard,Suite 475
CityMorrisville
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27560
Phone1-212-554-4484
Websitehttp://www.tgtherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Michael S. Weiss
  • Chairman of the Board, Chief Executive Officer and President
  • 15.84M
  • Sean A. Power
  • Chief Financial Officer, Treasurer and Corporate Secretary
  • 1.87M
  • Daniel Hume
  • Independent Director
  • 262.20K
  • Sagar Lonial, M.D.
  • Independent Director
  • 259.70K
  • Dr. Yann Echelard
  • Independent Director
  • 262.20K
  • Kenneth Hoberman
  • Independent Director
  • 264.70K
  • Laurence N. Charney
  • Lead Independent Director
  • 304.70K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025